Bronchopulmonary Dysplasia (BPD) affects approximately 10,000–15,000 preterm infants annually in the United States alone, with incidence rising as neonatal intensive care saves increasingly premature babies. BPD is a chronic lung disease that develops when extremely preterm infants — born before 28 weeks gestation — receive prolonged mechanical ventilation and oxygen therapy. The immature lung, exposed to hyperoxia, volutrauma, and inflammation, arrests its development: alveolar septation halts, capillary networks fail to form, and the lung becomes a simplified, fibrotic, poorly gas-exchanging organ. Current management — gentle ventilation strategies, postnatal steroids, surfactant, and diuretics — supports survival but does not reverse the structural damage. A significant proportion of BPD survivors face lifelong pulmonary morbidity: recurrent respiratory infections, asthma-like symptoms, exercise intolerance, and pulmonary hypertension. MSC therapy is being studied as a regenerative approach that targets the underlying biology — not just managing symptoms, but restoring the cellular architecture the preterm lung failed to build.[1]

What happens in the BPD lung

BPD is fundamentally a disease of arrested lung development. In the normal third trimester, the fetal lung undergoes a critical phase of alveolarization — the formation of millions of tiny air sacs (alveoli) from terminal saccules — alongside the parallel development of a dense capillary network for gas exchange. When a preterm infant is born at 24–27 weeks, this program is barely underway. The mechanical ventilation and supplemental oxygen that sustain life simultaneously unleash a triad of damage: oxidative stress from hyperoxia, barotrauma from positive-pressure ventilation, and a robust inflammatory cascade involving neutrophils, macrophages, and pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α).[2]

The result is a lung with fewer and larger alveoli. On histology, the BPD lung shows alveolar simplification — fewer septa, reduced internal surface area, dysmorphic pulmonary vasculature, and variable interstitial fibrosis. This is not scarred, normal lung; it is developmentally frozen lung. The clinical consequences — tachypnea, oxygen dependence, CO₂ retention, pulmonary hypertension — all trace back to this structural deficit.

The therapeutic gap is clear. Postnatal dexamethasone can reduce BPD severity but carries significant neurodevelopmental risk. Caffeine, vitamin A, and gentle ventilation help at the margins. None of these interventions regenerate lost alveoli or restore the pulmonary capillary bed. This is where MSC therapy enters the conversation — not as a replacement for current care, but as a regenerative adjunct that addresses what current care cannot.

Medical illustration of preterm neonatal lungs showing arrested alveolar development, inflammatory infiltrates, and MSC-mediated repair through paracrine signaling
BPD involves arrested alveolar development driven by oxygen toxicity, ventilator-induced injury, and inflammation. MSC therapy targets the inflammatory and regenerative pathways underlying this damage.

How MSC therapy works in the BPD lung

When clinical-grade Mesenchymal Stem Cells are delivered intravenously or intratracheally in the neonatal period, they do not engraft long-term as replacement lung cells. Their protective and regenerative effects are paracrine — mediated by a secretome of bioactive molecules that signal the injured lung to stop inflaming and start repairing. The evidence from preclinical models (rodent and lamb hyperoxia models) and early-phase human trials points to several complementary mechanisms:[3]

1. Anti-inflammatory protection

MSCs are exquisitely sensitive to inflammatory cues. In the hyperoxic BPD lung, they respond by secreting TSG-6 (TNF-stimulated gene 6), PGE2, and IL-10 — potent anti-inflammatory mediators that suppress alveolar macrophage activation, reduce neutrophil infiltration, and dampen the IL-1β/IL-6/TNF-α cytokine storm that drives tissue destruction. This is arguably the best-characterized mechanism and the primary rationale for early MSC administration.[4]

2. Alveolar and vascular regeneration

MSC-derived growth factors — VEGF (vascular endothelial growth factor), HGF (hepatocyte growth factor), and KGF (keratinocyte growth factor) — stimulate both alveolar epithelial type II cell proliferation and pulmonary capillary angiogenesis. In hyperoxia-exposed rodent pups, MSC treatment increases radial alveolar counts (the histological measure of alveolarization), restores septal thickness toward normal, and rebuilds the pulmonary microvasculature that had been obliterated by hyperoxia.[5]

3. Anti-fibrotic effects

The BPD lung has variable interstitial fibrosis that further limits gas exchange. MSC-derived factors — particularly HGF and TSG-6 — suppress TGF-β1 signaling, inhibit myofibroblast differentiation, and promote matrix metalloproteinase-mediated remodeling of existing fibrotic tissue. The net effect is a shift from fibrosis toward normal alveolar septation.[6]

4. Mitochondrial transfer

One of the more remarkable discoveries in MSC biology is the direct transfer of healthy mitochondria from MSCs to injured alveolar epithelial cells via tunneling nanotubes and extracellular vesicles. Hyperoxia damages mitochondrial DNA and impairs oxidative phosphorylation in the alveolar epithelium. Restoring mitochondrial function rescues cellular energy metabolism, reduces apoptosis, and supports surfactant production — functions that are critically impaired in the BPD lung.[7]

5. Immunomodulation and infection defense

Preterm infants with BPD are exquisitely vulnerable to respiratory infections, which trigger exacerbations and further lung injury. MSC therapy enhances the lung's antimicrobial defenses through secretion of LL-37 (cathelicidin) and β-defensins, while simultaneously suppressing the excessive inflammation that infection provokes — a dual action that conventional anti-inflammatory drugs cannot achieve.[8]

MSC therapy for bronchopulmonary dysplasia — paracrine mechanisms including anti-inflammatory, angiogenic, and alveolar regenerative effects in preterm lungs
MSC therapy in BPD is overwhelmingly paracrine — the cells signal repair rather than replacing tissue directly. Key mechanisms include anti-inflammatory protection, VEGF-driven angiogenesis, and alveolar growth factor secretion.

Preclinical evidence: what animal models tell us

The preclinical case for MSC therapy in BPD is robust and built on multiple animal species — primarily neonatal rodents exposed to hyperoxia (the standard BPD model) and preterm lambs (which better recapitulate the human preterm lung architecture). Key findings from the literature include:[9]

Key insight from preclinical work. Conditioned medium from MSCs — the growth factors and cytokines the cells secrete, without the cells themselves — reproduces most of the therapeutic benefit in hyperoxia models. This strongly supports the paracrine hypothesis and has spurred interest in cell-free products (exosomes, conditioned medium) as future BPD therapies that avoid the logistical complexity of live-cell administration.

Clinical evidence: what the human trials show

The translation of MSC therapy from bench to BPD bedside has been one of the more successful stories in neonatal regenerative medicine. Multiple phase I and phase II clinical trials have been conducted, primarily in South Korea and the United States, using umbilical cord blood-derived or umbilical cord tissue-derived MSCs:[10]

An important caveat. The published trials to date are small (typically 9–30 patients) and designed to establish safety and feasibility, not efficacy. They are encouraging but do not yet constitute proof that MSC therapy reduces BPD incidence or severity in a statistically definitive way. Larger randomized controlled trials are needed before MSC therapy can be considered a standard-of-care intervention for BPD.

Practical considerations: timing, route, and dosing

Based on the available preclinical and clinical data, the following treatment parameters are emerging as the most plausible for clinical translation:

Timing. The therapeutic window for BPD is broader than for acute neonatal brain injury. While earlier intervention — during the inflammatory phase of evolving BPD (typically days 5–14 of life in high-risk preterm infants) — is theoretically preferable, the MSC mechanism (paracrine, anti-inflammatory, regenerative) may provide benefit even in established BPD. The ideal timing likely depends on the specific goal: inflammation suppression (early) versus alveolar regeneration (later).

Route of administration. Two routes have been studied in human trials: intratracheal (direct instillation into the airways) and intravenous. Intratracheal delivery achieves higher local pulmonary concentrations and may be more efficient for lung-targeted effects, but it is invasive and requires the infant to be intubated. Intravenous delivery is less invasive, allows multiple doses, and capitalizes on the well-documented pulmonary first-pass effect — MSCs administered IV are transiently trapped in the pulmonary capillary bed, achieving high lung exposure before redistributing systemically.

Dosing. Published trials have used doses of 1×10⁷ to 2×10⁷ cells/kg, administered as a single dose. Whether repeated dosing (weekly or biweekly during the NICU stay) provides additional benefit is an open question being addressed in ongoing trials. The remarkable safety record of neonatal MSC therapy to date — no tumor formation, no infusion reactions, no excess adverse events — makes higher doses and repeated dosing intervals plausible for investigation.

Safety in the neonatal population

The safety profile of MSC therapy in preterm neonates deserves particular attention because this is one of the most vulnerable patient populations in medicine. Reassuringly, the safety data from published neonatal trials — in BPD, HIE, and other neonatal indications — are consistently benign:[11]

Limitations and realistic expectations

It is essential to state plainly what MSC therapy for BPD is and is not. It is an investigational therapy supported by strong preclinical rationale and encouraging phase I/II safety data. It is not a cure, and it does not replace current NICU management — gentle ventilation, optimal nutrition, infection prevention, and careful oxygen targeting remain the bedrock of BPD care.

Several important unknowns remain:

Families considering MSC therapy for a preterm infant with or at risk for BPD should engage with a clinical team experienced in both neonatal intensive care and cell therapy. The decision involves weighing the encouraging safety record and preclinical data against the absence of large-scale efficacy trials and the significant logistical demands of accessing cell therapy in the NICU setting.[12]

Frequently Asked Questions

What is bronchopulmonary dysplasia (BPD)?

BPD is a chronic lung disease that affects extremely preterm infants who require mechanical ventilation and oxygen therapy after birth. The immature lung arrests its development — alveolar septation stops, capillaries fail to form, and the lung develops a simplified, fibrotic architecture that impairs gas exchange. Approximately 40% of infants born before 28 weeks develop some degree of BPD.

How can stem cells help repair BPD lung damage?

MSCs work through paracrine signaling — they secrete anti-inflammatory molecules (TSG-6, IL-10), growth factors (VEGF, HGF, KGF) that stimulate alveolar and vascular regeneration, and anti-fibrotic factors that suppress scar formation. They do not need to become lung cells; they signal the infant's own lung to repair itself.

What evidence supports MSC therapy for BPD?

Preclinical studies in hyperoxic rodent and lamb models consistently show improved alveolarization, reduced inflammation, and decreased pulmonary hypertension after MSC treatment. Phase I and II human trials in South Korea and the United States have demonstrated safety and feasibility, with encouraging signals in BPD severity reduction. Larger confirmatory trials are ongoing.

Is MSC therapy safe for preterm babies?

Safety data from published neonatal MSC trials are reassuring: no tumor formation, no acute infusion reactions, no excess infections, and normal neurodevelopmental outcomes at 2–5 year follow-up. However, the total number of treated neonates remains small (under 200 in published trials), and continued vigilance in larger studies is necessary.

When is the best time to give MSCs for BPD?

The optimal timing is not yet established. Early administration (days 5–14 of life) during the inflammatory phase of evolving BPD is the approach used in most published trials and makes theoretical sense for suppressing the inflammatory cascade. However, the paracrine mechanism may also benefit infants with established BPD by stimulating alveolar regeneration, though this is less well studied.

How much does MSC therapy for BPD cost?

MSC therapy for BPD remains investigational and is not yet a standard-of-care treatment — costs vary by provider and country. At VELAR Center in Bangkok, comprehensive consultation includes candidacy evaluation, treatment protocol design, and an honest discussion of evidence, expected outcomes, and limitations based on the most current published data.

References

  1. Thébaud B, Goss KN, Laughon M, et al. Bronchopulmonary dysplasia. Nature Reviews Disease Primers. 2019;5(1):78. doi:10.1038/s41572-019-0127-7 ↩
  2. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine. 2001;163(7):1723-1729. doi:10.1164/ajrccm.163.7.2011060 ↩
  3. Ahn SY, Chang YS, Park WS. Mesenchymal stem cells for bronchopulmonary dysplasia: a comprehensive review of preclinical and clinical studies. Stem Cells Translational Medicine. 2021;10(2):198-210. doi:10.1002/sctm.20-0296 ↩
  4. Willis GR, Fernandez-Gonzalez A, Reis M, Mitsialis SA, Kourembanas S. Mesenchymal stromal cell exosomes improve alveolarization and pulmonary vascular development in experimental BPD. American Journal of Respiratory and Critical Care Medicine. 2018;197(1):104-116. doi:10.1164/rccm.201705-0921OC ↩
  5. Chang YS, Ahn SY, Yoo HS, et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. Journal of Pediatrics. 2014;164(5):966-972.e6. doi:10.1016/j.jpeds.2013.12.011 ↩
  6. Aslam M, Baveja R, Liang OD, et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. American Journal of Respiratory and Critical Care Medicine. 2009;180(11):1122-1130. doi:10.1164/rccm.200902-0242OC ↩
  7. Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nature Medicine. 2012;18(5):759-765. doi:10.1038/nm.2736 ↩
  8. Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010;28(12):2229-2238. doi:10.1002/stem.544 ↩
  9. Fung ME, Thébaud B. Stem cell-based therapy for neonatal lung disease. Cell and Tissue Research. 2014;356(1):161-169. doi:10.1007/s00441-013-1785-5 ↩
  10. Ahn SY, Chang YS, Sung SI, Park WS. Mesenchymal stem cells for severe intraventricular hemorrhage in preterm infants: phase I dose-escalation clinical trial. Stem Cells Translational Medicine. 2018;7(12):847-856. doi:10.1002/sctm.17-0218 ↩
  11. Namba F, Kitagawa H, Go S, et al. Mesenchymal stem cells for the prevention of bronchopulmonary dysplasia. Pediatrics International. 2020;62(9):1061-1067. doi:10.1111/ped.14271 ↩
  12. Pierro M, Thébaud B. Mesenchymal stem cells and the treatment of neonatal lung disease. Seminars in Fetal and Neonatal Medicine. 2021;26(6):101311. doi:10.1016/j.siny.2021.101311 ↩